ELI LILLY & CO (LLY)
US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (5/15/2024, 10:39:04 AM)
780.12
+17.44 (+2.29%)
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. The firm's subsidiary is POINT Biopharma Global Inc., which is a radiopharmaceutical company with a pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer. The firm's products are sold in over 110 countries.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000
CEO: David A. Ricks
Employees: 39000
Website: https://www.lilly.com/
LLY News
6 hours ago - The Motley FoolThese 2 Words Explain Why Eli Lilly Stock Is a Buy Right NowIts latest medicines for obesity and type 2 diabetes are selling rapidly.
7 hours ago - QuartzHow to solve the weight loss drug shortage, according to a top Eli Lilly executiveOnly a weight loss pill can meet demand that has led to shortages for drugs like Ozempic and Zepbound, an executive for the pharma giant said in an interview
The Church of Jesus Christ of Latter-day Saints added exposure to mega-cap tech stocks during the first quarter and Eli Lilly became a top 10 holding.
21 hours ago - CNBCHealthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey saysA wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
a day ago - CNBCPeople on Novo Nordisk's Wegovy maintain weight loss for up to four years, study saysThe results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
a day ago - The Motley Fool2 Top Pharma Stocks That Just Keep Getting Better and BetterBoth of these businesses are finding traction in a pair of major markets.
LLY Twits
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
